CD34 and breast cancer: We considered four scenarios, human brain datasets (Yang et al. 2022), human breast cancer only (Wu et al. 2021), mixed cancer [breast cancer and liver cancer (Ma et al. 2020)], and primary myelofibrosis (CD34+) (Parenti et al. 2021), each containing data from multiple heterogeneous sources to merge/integrate.